I don't think cytodyn can just create a clinical hold out of an abundance of safety when in reality they are pausing the trials to save money. that is an outright lie to investors. It was explained that there were a couple deaths in the trial and they did not know if it was treatment or placebo arm (it is blinded) so they want to investigate before proceeding. this is likely not what would have happened under Nader, but that is what they did. It is good because the process of recruiting patients is very difficult when it is an non fda approved drug for anything, any incident could stop all recruitment out of fear. getting answers if there is a safety problem leads to confidence in the doctor to keep pushing for recruitment rather than holding off.

It was also obvious that recruitment was going very slow and a clinical hold would not impact the speed of the trial much because it was already slow. I think current management knows the covid treatment indication train has left the station, not that it was a mistake to pursue, but it is not a top priority now. Long haulers will be a difficult path mostly because so little is known about the condition. it is good to show very positive results but if they don't know why people have long haulers then it is difficult to credit a treatment with solving it.